

The Levels of Soluble versus Insoluble Brain A β Distinguishing Normal and Pathologic Aging

Experimental Neurology

158, 328-337

DOI: [10.1006/exnr.1999.7085](https://doi.org/10.1006/exnr.1999.7085)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Anti-Aging Medicine LiteratureWatch. Rejuvenation Research, 1998, 1, 275-284.	0.2	0
2	Anti-Aging Medicine LiteratureWatch. Rejuvenation Research, 1999, 2, 295-309.	0.2	0
3	Soluble pool of A β amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Annals of Neurology, 1999, 46, 860-866.	2.8	1,721
4	Chapter 4. Secretase inhibitors as therapeutics for Alzheimer's disease. Annual Reports in Medicinal Chemistry, 2000, 35, 31-40.	0.5	12
5	Influence of lipoproteins on microglial degradation of Alzheimer's amyloid beta-protein. Microscopy Research and Technique, 2000, 50, 316-324.	1.2	42
6	Alzheimer's disease cybrids replicate β -amyloid abnormalities through cell death pathways. Annals of Neurology, 2000, 48, 148-155.	2.8	171
8	In vivo detection of amyloid plaques in a mouse model of Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 7609-7614.	3.3	211
9	Novel Method to Quantify Neuropil Threads in Brains from Elders With or Without Cognitive Impairment. Journal of Histochemistry and Cytochemistry, 2000, 48, 1627-1637.	1.3	77
10	Alzheimer-Related β -Pathology in the Perforant Path Target Zone and in the Hippocampal Stratum Oriens and Radiatum Correlates with Onset and Degree of Dementia. Experimental Neurology, 2000, 163, 98-110.	2.0	148
11	Chelation and Intercalation: Complementary Properties in a Compound for the Treatment of Alzheimer's Disease. Journal of Structural Biology, 2000, 130, 209-216.	1.3	81
12	Nicotine and amyloid formation. Biological Psychiatry, 2001, 49, 248-257.	0.7	70
13	Sublethal Concentrations of Prion Peptide PrP106-126 or the Amyloid Beta Peptide of Alzheimer's Disease Activates Expression of Proapoptotic Markers in Primary Cortical Neurons. Neurobiology of Disease, 2001, 8, 299-316.	2.1	66
14	Phenolic anti-inflammatory antioxidant reversal of A β ²⁵⁻³⁵ -induced cognitive deficits and neuropathology. Neurobiology of Aging, 2001, 22, 993-1005.	1.5	501
15	Reduction of cortical amyloid β levels in guinea pig brain after systemic administration of physostigmine. Neuroscience Letters, 2001, 310, 21-24.	1.0	39
16	Treatment with a Copper-Zinc Chelator Markedly and Rapidly Inhibits β -Amyloid Accumulation in Alzheimer's Disease Transgenic Mice. Neuron, 2001, 30, 665-676.	3.8	1,419
17	Transgenic mouse models of Alzheimer's disease. Physiology and Behavior, 2001, 73, 873-886.	1.0	164
18	The Natural History of Alzheimer's Disease: Minding the Gaps in Understanding the Mechanisms of Neurodegeneration. Research and Perspectives in Alzheimer's Disease, 2001, , 1-21.	0.1	0
19	Therapeutic targets in the biology of Alzheimer's disease. Current Opinion in Psychiatry, 2001, 14, 341-348.	3.1	14

#	ARTICLE	IF	CITATIONS
20	Conversion of brain apolipoprotein E to an insoluble form in a mouse model of Alzheimer disease. <i>NeuroReport</i> , 2001, 12, 1265-1270.	0.6	10
21	Neurotoxic A β peptides increase oxidative stress in vivo through NMDA-receptor and nitric-oxide-synthase mechanisms, and inhibit complex IV activity and induce a mitochondrial permeability transition in vitro. <i>Journal of Neurochemistry</i> , 2001, 76, 1050-1056.	2.1	187
22	Alzheimer's Disease: Physiological and Pathogenetic Role of the Amyloid Precursor Protein (APP), its A β -Amyloid Domain and Free A β -Amyloid Peptide. <i>Research and Perspectives in Alzheimer's Disease</i> , 2001, , 97-117.	0.1	3
23	Learning and Memory in Transgenic Mice Modeling Alzheimer's Disease. <i>Learning and Memory</i> , 2001, 8, 301-308.	0.5	205
24	Molecular chaperones and age-related degenerative disorders. <i>Advances in Cell Aging and Gerontology</i> , 2001, 7, 131-162.	0.1	23
25	Early-onset Amyloid Deposition and Cognitive Deficits in Transgenic Mice Expressing a Double Mutant Form of Amyloid Precursor Protein 695. <i>Journal of Biological Chemistry</i> , 2001, 276, 21562-21570.	1.6	820
26	Peripheral anti-A β antibody alters CNS and plasma A β clearance and decreases brain A β burden in a mouse model of Alzheimer's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 8850-8855.	3.3	1,269
27	Alzheimer's disease: Its diagnosis and pathogenesis. <i>International Review of Neurobiology</i> , 2001, 48, 167-217.	0.9	17
28	The galvanization of A β -amyloid in Alzheimer's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 7317-7319.	3.3	127
29	β -Secretase Processing in the Trans-Golgi Network Preferentially Generates Truncated Amyloid Species That Accumulate in Alzheimer's Disease Brain. <i>Journal of Biological Chemistry</i> , 2002, 277, 16278-16284.	1.6	157
30	Nonoverlapping but synergetic tau and APP pathologies in sporadic Alzheimer's disease. <i>Neurology</i> , 2002, 59, 398-407.	1.5	162
31	Brain to Plasma Amyloid-beta Efflux: a Measure of Brain Amyloid Burden in a Mouse Model of Alzheimer's Disease. <i>Science</i> , 2002, 295, 2264-2267.	6.0	544
32	Stable β -Secretase Activity and Presynaptic Cholinergic Markers During Progressive Central Nervous System Amyloidogenesis in Tg2576 Mice. <i>American Journal of Pathology</i> , 2002, 160, 731-738.	1.9	64
33	Localization of β -Secretase Memapsin 2 in the Brain of Alzheimer's Patients and Normal Aged Controls. <i>Experimental Neurology</i> , 2002, 175, 10-22.	2.0	40
34	Human and Murine ApoE Markedly Alters A β Metabolism before and after Plaque Formation in a Mouse Model of Alzheimer's Disease. <i>Neurobiology of Disease</i> , 2002, 9, 305-318.	2.1	248
35	The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to Therapeutics. <i>Science</i> , 2002, 297, 353-356.	6.0	12,113
36	Structure and location of amyloid beta peptide chains and arrays in Alzheimer's disease: new findings require reevaluation of the amyloid hypothesis and of tests of the hypothesis. <i>Neurobiology of Aging</i> , 2002, 23, 225-230.	1.5	22
37	A β as a bioflocculant: implications for the amyloid hypothesis of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2002, 23, 1051-1072.	1.5	140

#	ARTICLE	IF	CITATIONS
38	Metal complexing agents as therapies for Alzheimer's disease. <i>Neurobiology of Aging</i> , 2002, 23, 1031-1038.	1.5	303
39	Stereologic assessment of the total cortical volume occupied by amyloid deposits and its relationship with cognitive status in aging and Alzheimer's disease. <i>Neuroscience</i> , 2002, 112, 75-91.	1.1	101
40	β and C is for Clioquinol the AβCs of Alzheimer's disease. <i>Trends in Neurosciences</i> , 2002, 25, 121-123.	2	23
41	Response: β and C is for Clioquinol the AβCs of Alzheimer's disease. <i>Trends in Neurosciences</i> , 2002, 25, 123-124.	4.2	1
42	Repetitive Mild Brain Trauma Accelerates Aβ Deposition, Lipid Peroxidation, and Cognitive Impairment in a Transgenic Mouse Model of Alzheimer Amyloidosis. <i>Journal of Neuroscience</i> , 2002, 22, 446-454.	1.7	314
43	The Relationship between Aβ and Memory in the Tg2576 Mouse Model of Alzheimer's Disease. <i>Journal of Neuroscience</i> , 2002, 22, 1858-1867.	1.7	671
44	p35/Cdk5 pathway mediates soluble amyloid-β peptide-induced tau phosphorylation in vitro. <i>Journal of Neuroscience Research</i> , 2002, 69, 362-372.	1.3	91
45	Paradigm shifts in Alzheimer's disease and other neurodegenerative disorders: The emerging role of oligomeric assemblies. <i>Journal of Neuroscience Research</i> , 2002, 69, 567-577.	1.3	540
46	A Mathematical Model of the Impact of Novel Treatments on the Aβ Burden in the Alzheimer's Brain, CSF and Plasma. <i>Bulletin of Mathematical Biology</i> , 2002, 64, 1011-1031.	0.9	44
47	What Can Rodent Models Tell Us About Cognitive Decline in Alzheimer's Disease?. <i>Molecular Neurobiology</i> , 2003, 27, 249-276.	1.9	28
48	Characterization of amyloid β peptides from brain extracts of transgenic mice overexpressing the London mutant of human amyloid precursor protein. <i>Journal of Neurochemistry</i> , 2003, 84, 602-609.	2.1	44
49	Brain levels of CDK5 activator p25 are not increased in Alzheimer's or other neurodegenerative diseases with neurofibrillary tangles. <i>Journal of Neurochemistry</i> , 2003, 86, 572-581.	2.1	81
50	Current Status of Metals as Therapeutic Targets in Alzheimer's Disease. <i>Journal of the American Geriatrics Society</i> , 2003, 51, 1143-1148.	1.3	198
51	Zinc takes the center stage: its paradoxical role in Alzheimer's disease. <i>Brain Research Reviews</i> , 2003, 41, 44-56.	9.1	227
52	The metallobiology of Alzheimer's disease. <i>Trends in Neurosciences</i> , 2003, 26, 207-214.	4.2	1,191
53	Lipopolysaccharide-induced-neuroinflammation increases intracellular accumulation of amyloid precursor protein and amyloid β peptide in APPswe transgenic mice. <i>Neurobiology of Disease</i> , 2003, 14, 133-145.	2.1	374
54	In Vitro Characterization of Conditions for Amyloid-β Peptide Oligomerization and Fibrillogenesis. <i>Journal of Biological Chemistry</i> , 2003, 278, 11612-11622.	1.6	879
55	Aβ1-42 promotes cholinergic sprouting in patients with AD and Lewy body variant of AD. <i>Neurology</i> , 2003, 61, 206-211.	1.5	54

#	ARTICLE	IF	CITATIONS
56	Apoptotic Neuronal Cell Death Induced by the Non-fibrillar Amyloid- β Peptide Proceeds through an Early Reactive Oxygen Species-dependent Cytoskeleton Perturbation. <i>Journal of Biological Chemistry</i> , 2003, 278, 3437-3445.	1.6	102
57	Neurofibrillary Tangles, Amyloid, and Memory in Aging and Mild Cognitive Impairment. <i>Archives of Neurology</i> , 2003, 60, 729.	4.9	491
58	Copper, Zinc, and the Metallobiology of Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2003, 17, 147-150.	0.6	103
59	Membrane cholesterol interferes with neuronal apoptosis induced by soluble oligomers but not fibrils of the amyloid- β peptide. <i>FASEB Journal</i> , 2004, 18, 836-838.	0.2	82
60	Assessment of the Bioactivity of Antibodies against β -Amyloid Peptide in vitro and in vivo. <i>Neurodegenerative Diseases</i> , 2004, 1, 160-167.	0.8	11
61	MAPK recruitment by beta-amyloid in organotypic hippocampal slice cultures depends on physical state and exposure time. <i>Journal of Neurochemistry</i> , 2004, 91, 349-361.	2.1	105
62	Vitamin E reduces amyloidosis and improves cognitive function in Tg2576 mice following repetitive concussive brain injury. <i>Journal of Neurochemistry</i> , 2004, 90, 758-764.	2.1	147
63	Alzheimer's β -peptide oligomer formation at physiologic concentrations. <i>Analytical Biochemistry</i> , 2004, 335, 81-90.	1.1	111
64	Metal-protein attenuating compounds and Alzheimer's disease. <i>Expert Opinion on Investigational Drugs</i> , 2004, 13, 1585-1592.	1.9	60
65	Aberrant expressions of pathogenic phenotype in Alzheimer's diseased transgenic mice carrying NSE-controlled APPsw. <i>Experimental Neurology</i> , 2004, 186, 20-32.	2.0	59
66	The lipophilic metal chelator DP-109 reduces amyloid pathology in brains of human β -amyloid precursor protein transgenic mice. <i>Neurobiology of Aging</i> , 2004, 25, 1315-1321.	1.5	196
67	β localization in abnormal endosomes: association with earliest β elevations in AD and Down syndrome. <i>Neurobiology of Aging</i> , 2004, 25, 1263-1272.	1.5	338
68	Deciphering the Molecular Basis of Memory Failure in Alzheimer's Disease. <i>Neuron</i> , 2004, 44, 181-193.	3.8	1,127
69	Reduced levels of β 40 and β 42 in brains of smoking controls and Alzheimer's patients. <i>Neurobiology of Disease</i> , 2004, 15, 351-360.	2.1	67
70	Age-related myelin breakdown: a developmental model of cognitive decline and Alzheimer's disease. <i>Neurobiology of Aging</i> , 2004, 25, 5-18.	1.5	834
71	Amyloid β Degradation: A Challenging Task for Brain Peptidases. , 2005, 38, 129-145.		18
72	The Impact of Novel Treatments on β Burden in Alzheimer's Disease: Insights from A Mathematical Model. , 2005, , 839-865.		2
73	Synaptic plasticity disruption by amyloid β protein: modulation by potential Alzheimer's disease modifying therapies. <i>Biochemical Society Transactions</i> , 2005, 33, 563-567.	1.6	72

#	ARTICLE	IF	CITATIONS
74	Globular amyloid beta-peptide1-42 oligomer - a homogenous and stable neuropathological protein in Alzheimer's disease. <i>Journal of Neurochemistry</i> , 2005, 95, 834-847.	2.1	527
75	Subtype-specific actions of $\hat{1}^2$ -amyloid peptides on recombinant human neuronal nicotinic acetylcholine receptors ($\hat{1}^{\pm} 7$, $\hat{1}^{\pm} 4\hat{1}^2 2$, $\hat{1}^{\pm} 3\hat{1}^2 4$) expressed in <i>Xenopus laevis</i> oocytes. <i>British Journal of Pharmacology</i> , 2005, 146, 2.7 964-971.		41
76	Amyloid $\hat{1}^2$ protein immunotherapy neutralizes $\hat{A}\hat{1}^2$ oligomers that disrupt synaptic plasticity in vivo. <i>Nature Medicine</i> , 2005, 11, 556-561.	15.2	485
77	Metals and amyloid- $\hat{1}^2$ in Alzheimer's disease. <i>International Journal of Experimental Pathology</i> , 2005, 86, 147-159.	0.6	303
78	What is the dominant $\hat{a}\hat{1}^2$ species in human brain tissue? A review. <i>Neurotoxicity Research</i> , 2005, 7, 29-41.	1.3	41
79	Early Changes in Behavior Deficits, Amyloid $\hat{1}^2$ -42 Deposits and MAPK Activation in Doubly Transgenic Mice Co-expressing NSE-Controlled Human Mutant PS2 and APPsw. <i>Cellular and Molecular Neurobiology</i> , 2005, 25, 881-898.	1.7	6
80	Decreased Nephilysin Immunoreactivity in Alzheimer Disease, but Not in Pathological Aging. <i>Journal of Neuropathology and Experimental Neurology</i> , 2005, 64, 378-385.	0.9	72
81	Proteomic determination of widespread detergent insolubility, including $\hat{A}\hat{1}^2$ but not tau, early in the pathogenesis of Alzheimer's disease. <i>FASEB Journal</i> , 2005, 19, 1923-1925.	0.2	46
82	Quantitative Measurement of Changes in Amyloid- $\hat{1}^2$ (40) in the Rat Brain and Cerebrospinal Fluid following Treatment with the $\hat{1}^3$ -Secretase Inhibitor LY-411575 [N2-[(2S)-2-(3,5-Difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide]. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 313, 902-908.	1.8	103
83	Imagem oblivionis: the prospects of neuroimaging for early detection of Alzheimer's disease. <i>Journal of Clinical Neuroscience</i> , 2005, 12, 221-230.	0.8	51
84	Modulation of Alzheimer's pathology by cerebro-ventricular grafting of hybridoma cells expressing antibodies against $\hat{A}\hat{1}^2$ in vivo. <i>FEBS Letters</i> , 2005, 579, 753-756.	1.3	8
85	Pathophysiology of Alzheimer's Disease. <i>Neuroimaging Clinics of North America</i> , 2005, 15, 727-753.	0.5	68
86	Certain Inhibitors of Synthetic Amyloid $\hat{A}\hat{1}^2$ -Peptide ($\hat{A}\hat{A}$) Fibrillogenesis Block Oligomerization of Natural $\hat{A}\hat{A}$ and Thereby Rescue Long-Term Potentiation. <i>Journal of Neuroscience</i> , 2005, 25, 2455-2462.	1.7	286
87	Amyloid $\hat{1}^2$ -Protein: \hat{A} Monomer Structure and Early Aggregation States of $\hat{A}\hat{1}^2$ 42 and Its Pro19Alloform. <i>Journal of the American Chemical Society</i> , 2005, 127, 2075-2084.	6.6	321
88	$\hat{1}^2$ -Amyloid Mediated Nitration of Manganese Superoxide Dismutase. <i>American Journal of Pathology</i> , 2006, 168, 1608-1618.	1.9	129
89	Metabolism of amyloid $\hat{1}^2$ peptide and pathogenesis of Alzheimer's disease. <i>Neuroscience Research</i> , 2006, 54, 235-253.	1.0	93
90	La Lunga Attesa: Towards a Molecular Approach to Neuroimaging and Therapeutics in Alzheimer's Disease. <i>Neuroradiology Journal</i> , 2006, 19, 453-474.	0.6	12
91	Chaperone Suppression of Aggregated Protein Toxicity. , 2006, , 137-164.		1

#	ARTICLE	IF	CITATIONS
92	Quantification of Alzheimer pathology in ageing and dementia: age-related accumulation of amyloid-beta(42) peptide in vascular dementia. <i>Neuropathology and Applied Neurobiology</i> , 2006, 32, 103-118.	1.8	131
93	Biotin-avidin interaction-based screening assay for Alzheimer's β -peptide oligomer inhibitors. <i>Analytical Biochemistry</i> , 2006, 356, 265-272.	1.1	38
94	Protein Misfolding, Functional Amyloid, and Human Disease. <i>Annual Review of Biochemistry</i> , 2006, 75, 333-366.	5.0	5,737
95	Ex Situ Atomic Force Microscopy Analysis of β -Amyloid Self-Assembly and Deposition on a Synthetic Template. <i>Langmuir</i> , 2006, 22, 6977-6985.	1.6	28
96	Amyloid beta-protein monomer structure: A computational and experimental study. <i>Protein Science</i> , 2006, 15, 420-428.	3.1	236
97	Separation and analysis of the soluble trimer of β 40 and its effects on the rise in intracellular calcium. <i>Science Bulletin</i> , 2006, 51, 830-838.	4.3	3
98	Soluble oligomers of amyloid- β peptide induce neuronal apoptosis by activating a cPLA2-dependent sphingomyelinase-ceramide pathway. <i>Neurobiology of Disease</i> , 2006, 23, 178-189.	2.1	187
99	Mean age-of-onset of familial Alzheimer disease caused by presenilin mutations correlates with both increased β 42 and decreased β 40. <i>Human Mutation</i> , 2006, 27, 686-695.	1.1	306
100	Differential modulation of plasma β -amyloid by insulin in patients with Alzheimer disease. <i>Neurology</i> , 2006, 66, 1506-1510.	1.5	93
101	β 1-42 stimulates actin polymerization in hippocampal neurons through Rac1 and Cdc42 Rho GTPases. <i>Journal of Cell Science</i> , 2007, 120, 279-288.	1.2	95
102	SPECIFIC MECHANISM FOR BLOOD INFLOW STIMULATION IN BRAIN AREA PRONE TO ALZHEIMER'S DISEASE LESIONS. <i>International Journal of Neuroscience</i> , 2007, 117, 1425-1442.	0.8	4
103	Association of Increased Cortical Soluble β 42 Levels With Diffuse Plaques After Severe Brain Injury in Humans. <i>Archives of Neurology</i> , 2007, 64, 541.	4.9	131
104	Cortical biochemistry in MCI and Alzheimer disease: Lack of correlation with clinical diagnosis. <i>Neurology</i> , 2007, 68, 757-763.	1.5	54
105	Natural Oligomers of the Alzheimer Amyloid- β Protein Induce Reversible Synapse Loss by Modulating an NMDA-Type Glutamate Receptor-Dependent Signaling Pathway. <i>Journal of Neuroscience</i> , 2007, 27, 2866-2875.	1.7	1,445
106	2-(2-[2-Dimethylaminothiazol-5-yl]Ethenyl)-6-(2-[Fluoro]Ethoxy)Benzoxazole: A Novel PET Agent for In Vivo Detection of Dense Amyloid Plaques in Alzheimer's Disease Patients. <i>Journal of Nuclear Medicine</i> , 2007, 48, 553-561.	2.8	214
107	The curlin nucleator protein, CsgB, contains an amyloidogenic domain that directs CsgA polymerization. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 12494-12499.	3.3	240
108	Acide docosahexa- ω -3 que et maladie d'Alzheimer : des raisons espérer ?. <i>Oleagineux Corps Gras Lipides</i> , 2007, 14, 16-24.	0.2	0
109	Molecular determinants of Alzheimer's disease β peptide neurotoxicity. <i>Future Neurology</i> , 2007, 2, 397-409.	0.9	9

#	ARTICLE	IF	CITATIONS
110	The role of intracellular amyloid β in Alzheimer's disease. <i>Progress in Neurobiology</i> , 2007, 83, 131-139.	2.8	112
111	Dysregulation of dynorphins in Alzheimer disease. <i>Neurobiology of Aging</i> , 2007, 28, 1700-1708.	1.5	60
112	The redox chemistry of the Alzheimer's disease amyloid β peptide. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2007, 1768, 1976-1990.	1.4	533
113	A mechanistic link between oxidative stress and membrane mediated amyloidogenesis revealed by infrared spectroscopy. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2007, 1768, 1913-1922.	1.4	31
114	Metal Ions and Alzheimer's Disease. , 2007, , 333-361.		0
115	Hippocampal slice cultures integrated with multi-electrode arrays: a model for study of long-term drug effects on synaptic activity. <i>Drug Development Research</i> , 2007, 68, 84-93.	1.4	8
116	Amelioration of early cognitive deficits by aged garlic extract in Alzheimer's transgenic mice. <i>Phytotherapy Research</i> , 2007, 21, 629-640.	2.8	82
117	Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β -peptide. <i>Nature Reviews Molecular Cell Biology</i> , 2007, 8, 101-112.	16.1	4,267
118	A β Oligomers ? a decade of discovery. <i>Journal of Neurochemistry</i> , 2007, 101, 1172-1184.	2.1	1,795
119	Expression of APP pathway mRNAs and proteins in Alzheimer's disease. <i>Brain Research</i> , 2007, 1161, 116-123.	1.1	159
120	Effects of chemical chaperones on oxidative stress and detergent-insoluble species formation following conditional expression of amyloid precursor protein carboxy-terminal fragment. <i>Neurobiology of Disease</i> , 2007, 25, 427-437.	2.1	38
121	β solubility and deposition during AD progression and in APP ^{PS-1} knock-in mice. <i>Neurobiology of Disease</i> , 2007, 27, 301-311.	2.1	75
122	Reduced CXCL12/CXCR4 results in impaired learning and is downregulated in a mouse model of Alzheimer disease. <i>Neurobiology of Disease</i> , 2007, 28, 143-153.	2.1	71
123	Differentiating Alzheimer disease-associated aggregates with small molecules. <i>Neurobiology of Disease</i> , 2007, 28, 251-260.	2.1	71
124	Fibrillar and Oligomeric beta-Amyloid as Distinct Local Biomarkers for Alzheimer's Disease. <i>Annals of the New York Academy of Sciences</i> , 2007, 1097, 239-258.	1.8	17
125	Alterations in presenilin 1 processing by amyloid- β peptide in the rat retina. <i>Experimental Brain Research</i> , 2007, 181, 69-77.	0.7	4
126	Properties of scyllo-inositol as a therapeutic treatment of AD-like pathology. <i>Journal of Molecular Medicine</i> , 2007, 85, 603-611.	1.7	114
127	Solid-phase extraction enhances detection of beta-amyloid peptides in plasma and enables β quantification following passive immunization with β antibodies. <i>Journal of Neuroscience Methods</i> , 2008, 169, 16-22.	1.3	26

#	ARTICLE	IF	CITATIONS
128	Therapeutics for Alzheimer's Disease Based on the Metal Hypothesis. <i>Neurotherapeutics</i> , 2008, 5, 421-432.	2.1	512
129	Delineating the Mechanism of Alzheimer's Disease A β Peptide Neurotoxicity. <i>Neurochemical Research</i> , 2008, 33, 526-532.	1.6	105
130	Cholinergic and glutamatergic alterations beginning at the early stages of Alzheimer disease: participation of the phospholipase A2 enzyme. <i>Psychopharmacology</i> , 2008, 198, 1-27.	1.5	82
131	Acridine derivatives inhibit lysozyme aggregation. <i>European Biophysics Journal</i> , 2008, 37, 1261-1270.	1.2	61
133	The ART of Loss: A β Imaging in the Evaluation of Alzheimer's Disease and other Dementias. <i>Molecular Neurobiology</i> , 2008, 38, 1-15.	1.9	94
134	Reduction of Alzheimer's Disease Amyloid Plaque Load in Transgenic Mice by D3, a D-enantiomeric Peptide Identified by Mirror Image Phage Display. <i>ChemMedChem</i> , 2008, 3, 1848-1852.	1.6	115
135	Quartz crystal microbalance analysis of growth kinetics for aggregation intermediates of the amyloid- β protein. <i>Analytical Biochemistry</i> , 2008, 378, 15-24.	1.1	55
136	Brain oxidative stress in a triple-transgenic mouse model of Alzheimer disease. <i>Free Radical Biology and Medicine</i> , 2008, 44, 2051-2057.	1.3	304
137	Amyloid flirting with synaptic failure: Towards a comprehensive view of Alzheimer's disease pathogenesis. <i>European Journal of Pharmacology</i> , 2008, 585, 109-118.	1.7	52
138	Short-term exercise in aged Tg2576 mice alters neuroinflammation and improves cognition. <i>Neurobiology of Disease</i> , 2008, 30, 121-129.	2.1	168
139	A β deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease. <i>Neuropsychologia</i> , 2008, 46, 1688-1697.	0.7	272
140	Amyloid β -Cu ²⁺ Complexes in both Monomeric and Fibrillar Forms Do Not Generate H ₂ O ₂ Catalytically but Quench Hydroxyl Radicals. <i>Biochemistry</i> , 2008, 47, 11653-11664.	1.2	113
141	N-truncated amyloid- β oligomers induce learning impairment and neuronal apoptosis. <i>Neurobiology of Aging</i> , 2008, 29, 1319-1333.	1.5	65
142	Amyloid fibrils. <i>Prion</i> , 2008, 2, 112-117.	0.9	392
143	Alzheimer Disease Pathology As a Host Response. <i>Journal of Neuropathology and Experimental Neurology</i> , 2008, 67, 523-531.	0.9	150
144	Soluble amyloid- β peptides potently disrupt hippocampal synaptic plasticity in the absence of cerebrovascular dysfunction in vivo. <i>Brain</i> , 2008, 131, 2414-2424.	3.7	80
145	Introspective analysis of amyloid as the cause of Alzheimer's disease: alternative model proposed. <i>Future Neurology</i> , 2008, 3, 527-536.	0.9	0
146	The Seed Extract of <i>Cassia obtusifolia</i> Offers Neuroprotection to Mouse Hippocampal Cultures. <i>Journal of Pharmacological Sciences</i> , 2008, 107, 380-392.	1.1	63

#	ARTICLE	IF	CITATIONS
147	Chapter 3 Noncovalent Protein Interactions. Comprehensive Analytical Chemistry, 2008, , 63-82.	0.7	0
148	The Last Tangle of Tau. Journal of Alzheimer's Disease, 2008, 14, 441-447.	1.2	25
149	Computational insights into the development of novel therapeutic strategies for Alzheimer's disease. Future Medicinal Chemistry, 2009, 1, 119-135.	1.1	3
150	Microglia Mediate the Clearance of Soluble A β through Fluid Phase Macropinocytosis. Journal of Neuroscience, 2009, 29, 4252-4262.	1.7	362
151	Cortical α 7 Nicotinic Acetylcholine Receptor and β -Amyloid Levels in Early Alzheimer Disease. Archives of Neurology, 2009, 66, 646-51.	4.9	59
152	Modulation and Detection of Tau Aggregation with Small-Molecule Ligands. Current Alzheimer Research, 2009, 6, 409-414.	0.7	21
153	Relevance of Transgenic Mouse Models to Human Alzheimer Disease. Journal of Biological Chemistry, 2009, 284, 6033-6037.	1.6	129
154	Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction. Neurobiology of Disease, 2009, 35, 352-358.	2.1	298
155	Biochemical and immunohistochemical analysis of an Alzheimer's disease mouse model reveals the presence of multiple cerebral A β assembly forms throughout life. Neurobiology of Disease, 2009, 36, 293-302.	2.1	117
157	Beta-amyloid protein (25-35) disrupts hippocampal network activity: Role of Fyn-kinase. Hippocampus, 2010, 20, 78-96.	0.9	66
158	Alzheimer's Disease: From Pathology to Therapeutic Approaches. Angewandte Chemie - International Edition, 2009, 48, 3030-3059.	7.2	544
159	Amyloid Imaging in Alzheimer's Disease and Other Dementias. Brain Imaging and Behavior, 2009, 3, 246-261.	1.1	32
160	Alzheimer's disease: synaptic dysfunction and A β . Molecular Neurodegeneration, 2009, 4, 48.	4.4	388
161	Clearance mechanisms of Alzheimer's amyloid- β peptide: implications for therapeutic design and diagnostic tests. Molecular Psychiatry, 2009, 14, 469-486.	4.1	208
162	Characterisation of two antibodies to oligomeric A β and their use in ELISAs on human brain tissue homogenates. Journal of Neuroscience Methods, 2009, 176, 206-212.	1.3	46
163	Photocontrol of β -Amyloid Peptide (1-40) Fibril Growth in the Presence of a Photosurfactant. Journal of Physical Chemistry B, 2009, 113, 6164-6172.	1.2	19
164	Chapter 3 Small-Molecule Protein-Protein Interaction Inhibitors as Therapeutic Agents for Neurodegenerative Diseases: Recent Progress and Future Directions. Annual Reports in Medicinal Chemistry, 2009, , 51-69.	0.5	8
165	Amyloid- β expression in retrosplenial cortex of triple transgenic mice: relationship to cholinergic axonal afferents from medial septum. Neuroscience, 2009, 164, 1334-1346.	1.1	16

#	ARTICLE	IF	CITATIONS
166	Comparison of A β levels in the brain of familial and sporadic Alzheimer's disease. <i>Neurochemistry International</i> , 2009, 55, 243-252.	1.9	60
167	Metallo-complex activation of neuroprotective signalling pathways as a therapeutic treatment for Alzheimer's disease. <i>Molecular BioSystems</i> , 2009, 5, 134-142.	2.9	30
168	Galantamine inhibits A β -amyloid aggregation and cytotoxicity. <i>Journal of the Neurological Sciences</i> , 2009, 280, 49-58.	0.3	85
169	Comparison study of amyloid PET and voxel-based morphometry analysis in mild cognitive impairment and Alzheimer's disease. <i>Journal of the Neurological Sciences</i> , 2009, 285, 100-108.	0.3	53
170	<i>Molecular Imaging in Neurology and Psychiatry</i> , 2009, , 255-298.		1
171	Is Alzheimer's Disease a Result of Presynaptic Failure? - Synaptic Dysfunctions Induced by Oligomeric A β -Amyloid. <i>Reviews in the Neurosciences</i> , 2009, 20, 1-12.	1.4	125
172	The Quest for Small Molecules as Amyloid Inhibiting Therapies for Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2009, 17, 33-47.	1.2	64
173	Hyperhomocysteinemia Increases A β -Amyloid by Enhancing Expression of A β -Secretase and Phosphorylation of Amyloid Precursor Protein in Rat Brain. <i>American Journal of Pathology</i> , 2009, 174, 1481-1491.	1.9	137
175	Amyloid-A β Peptide and Oligomers in the Brain and Cerebrospinal Fluid of Aged Canines. <i>Journal of Alzheimer's Disease</i> , 2010, 20, 637-646.	1.2	69
176	Alzheimer's Disease Amyloid A β -Protein and Synaptic Function. <i>NeuroMolecular Medicine</i> , 2010, 12, 13-26.	1.8	122
177	Searching for new animal models of Alzheimer's disease. <i>European Journal of Pharmacology</i> , 2010, 626, 57-63.	1.7	44
178	Design of an orally efficacious hydroxyethylamine (HEA) BACE-1 inhibitor in a preclinical animal model. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 6231-6236.	1.0	44
179	Preparation and characterization of toxic A β aggregates for structural and functional studies in Alzheimer's disease research. <i>Nature Protocols</i> , 2010, 5, 1186-1209.	5.5	225
180	Oligomeric A β in Alzheimer's Disease: Relationship to Plaque and Tangle Pathology, APOE Genotype and Cerebral Amyloid Angiopathy. <i>Brain Pathology</i> , 2010, 20, 468-480.	2.1	57
181	Higher Soluble Amyloid A β Concentration in Frontal Cortex of Young Adults than in Normal Elderly or Alzheimer's Disease. <i>Brain Pathology</i> , 2010, 20, 787-793.	2.1	41
182	Changes with Age in the Activities of A β -Secretase and the A β -Degrading Enzymes Nephilysin, Insulin-Degrading Enzyme and Angiotensin-Converting Enzyme. <i>Brain Pathology</i> , 2010, 20, 794-802.	2.1	82
183	Neocortical Variation of A β Load in Fully Expressed, Pure Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2010, 19, 57-68.	1.2	19
184	Cognitive Deficits Associated with Alteration of Synaptic Metaplasticity Precede Plaque Deposition in A β PP23 Transgenic Mice. <i>Journal of Alzheimer's Disease</i> , 2010, 21, 1367-1381.	1.2	35

#	ARTICLE	IF	CITATIONS
185	Cystatin C Protects Neuronal Cells from Amyloid- β -induced Toxicity. <i>Journal of Alzheimer's Disease</i> , 2010, 19, 885-894.	1.2	105
186	Amyloid β -Protein Dimers Rapidly Form Stable Synaptotoxic Protofibrils. <i>Journal of Neuroscience</i> , 2010, 30, 14411-14419.	1.7	232
187	Generation and Therapeutic Efficacy of Highly Oligomer-Specific β -Amyloid Antibodies. <i>Journal of Neuroscience</i> , 2010, 30, 10369-10379.	1.7	97
188	The presence of sodium dodecyl sulphate-stable A β dimers is strongly associated with Alzheimer-type dementia. <i>Brain</i> , 2010, 133, 1328-1341.	3.7	229
189	Amyloid PET Ligands for Dementia. <i>PET Clinics</i> , 2010, 5, 33-53.	1.5	23
190	The Cu(II)/A β /Human Serum Albumin Model of Control Mechanism for Copper-Related Amyloid Neurotoxicity. <i>Chemical Research in Toxicology</i> , 2010, 23, 298-308.	1.7	49
191	Amyloid- β production in aged guinea pigs: atropine-induced enhancement is reversed by naloxone. <i>Neuroscience Letters</i> , 2010, 480, 83-86.	1.0	8
192	Intensification of long-term memory deficit by chronic stress and prevention by nicotine in a rat model of Alzheimer's disease. <i>Molecular and Cellular Neurosciences</i> , 2010, 45, 289-296.	1.0	36
193	Neurogenesis in mouse models of Alzheimer's disease. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2010, 1802, 872-880.	1.8	84
194	RS-0406 Arrests Amyloid- β Oligomer-Induced Behavioural Deterioration In Vivo. <i>Behavioural Brain Research</i> , 2010, 210, 32-37.	1.2	17
195	Differential roles of phospholipases A2 in neuronal death and neurogenesis: Implications for Alzheimer disease. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2010, 34, 1381-1389.	2.5	29
196	The Effect of Alzheimer's A β Aggregation State on the Permeation of Biomimetic Lipid Vesicles. <i>Langmuir</i> , 2010, 26, 17260-17268.	1.6	92
197	LPYFDa Neutralizes Amyloid- β -Induced Memory Impairment and Toxicity. <i>Journal of Alzheimer's Disease</i> , 2010, 19, 991-1005.	1.2	29
198	Phenyldiazanyl benzothiazole derivatives as probes for in vivo imaging of neurofibrillary tangles in Alzheimer's disease brains. <i>MedChemComm</i> , 2011, 2, 596.	3.5	38
199	Neuronal Death Induced by Nanomolar Amyloid β Is Mediated by Primary Phagocytosis of Neurons by Microglia. <i>Journal of Biological Chemistry</i> , 2011, 286, 39904-39913.	1.6	185
200	Curcuminoid Binds to Amyloid- β 1-42 Oligomer and Fibril. <i>Journal of Alzheimer's Disease</i> , 2011, 24, 33-42.	1.2	80
201	Soluble A β Seeds Are Potent Inducers of Cerebral β -Amyloid Deposition. <i>Journal of Neuroscience</i> , 2011, 31, 14488-14495.	1.7	203
202	Endothelin receptor antagonists: Potential in Alzheimer's disease. <i>Pharmacological Research</i> , 2011, 63, 525-531.	3.1	40

#	ARTICLE	IF	CITATIONS
203	Submicromolar A β ⁴² reduces hippocampal glutamate receptors and presynaptic markers in an aggregation-dependent manner. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2011, 1812, 1664-1674.	1.8	18
204	Soluble A β ² levels correlate with cognitive deficits in the 12-month-old APP ^{swe} /PS1 ^{dE9} mouse model of Alzheimer's disease. <i>Behavioural Brain Research</i> , 2011, 222, 342-350.	1.2	88
205	Protection against A β -mediated rapid disruption of synaptic plasticity and memory by memantine. <i>Neurobiology of Aging</i> , 2011, 32, 614-623.	1.5	65
206	The selective and competitive N-methyl-D-aspartate receptor antagonist, (â''-)-6-phosphonomethyl-deca-hydroisoquinoline-3-carboxylic acid, prevents synaptic toxicity induced by amyloid- β in mice. <i>Neuroscience</i> , 2011, 192, 631-641.	1.1	21
207	Research Towards Tau Imaging. <i>Journal of Alzheimer's Disease</i> , 2011, 26, 147-157.	1.2	39
208	Impact of Oxidative - Nitrosative Stress on Cholinergic Presynaptic Function. , 2011, , .		2
209	Insights into Alzheimer disease pathogenesis from studies in transgenic animal models. <i>Clinics</i> , 2011, 66, 45-54.	0.6	91
210	Knockdown of BACE1-AS Nonprotein-Coding Transcript Modulates Beta-Amyloid-Related Hippocampal Neurogenesis. <i>International Journal of Alzheimer's Disease</i> , 2011, 2011, 1-11.	1.1	112
211	Lowâ€œ oligomers as therapeutic targets of Alzheimerâ€™s disease. <i>Journal of Neurochemistry</i> , 2011, 117, 19-28.	2.1	80
212	Generation of dendritic cells and macrophages from human induced pluripotent stem cells aiming at cell therapy. <i>Gene Therapy</i> , 2011, 18, 874-883.	2.3	128
213	Up-regulation of calyntenin-3 by β -amyloid increases vulnerability of cortical neurons. <i>FEBS Letters</i> , 2011, 585, 651-656.	1.3	17
214	Alzheimerâ€™s disease: ageing-related or age-related? New hypotheses from an old debate. <i>Neurological Sciences</i> , 2011, 32, 1241-1247.	0.9	7
215	c-Jun N-terminal Kinase Regulates Soluble A β Oligomers and Cognitive Impairment in AD Mouse Model. <i>Journal of Biological Chemistry</i> , 2011, 286, 43871-43880.	1.6	74
216	Aβ Oligomers Induce Glutamate Release from Hippocampal Neurons. <i>Current Alzheimer Research</i> , 2011, 8, 552-562.	0.7	88
217	Alzheimer's Disease. <i>Cold Spring Harbor Perspectives in Biology</i> , 2011, 3, a004457-a004457.	2.3	348
218	Alzheimer's Disease Brain-Derived Amyloid- β -Mediated Inhibition of LTP<i>In Vivo</i>Is Prevented by Immunotargeting Cellular Prion Protein. <i>Journal of Neuroscience</i> , 2011, 31, 7259-7263.	1.7	215
219	Is the Amyloid Hypothesis of Alzheimer's disease therapeutically relevant?. <i>Biochemical Journal</i> , 2012, 446, 165-177.	1.7	89
220	Endothelin-1 is Elevated in Alzheimer's Disease and Upregulated by Amyloid- β . <i>Journal of Alzheimer's Disease</i> , 2012, 29, 853-861.	1.2	95

#	ARTICLE	IF	CITATIONS
222	A β oligomer toxicity inhibitor protects memory in models of synaptic toxicity. <i>British Journal of Pharmacology</i> , 2012, 167, 383-392.	2.7	15
223	Selectivity requirements for diagnostic imaging of neurofibrillary lesions in Alzheimer's disease: A simulation study. <i>NeuroImage</i> , 2012, 60, 1724-1733.	2.1	20
224	Alzheimer's Disease and Amyloid: Culprit or Coincidence?. <i>International Review of Neurobiology</i> , 2012, 102, 277-316.	0.9	67
225	TDP-43: A new player on the AD field?. <i>Experimental Neurology</i> , 2012, 237, 90-95.	2.0	25
226	The levels of water-soluble and triton-soluble A β are increased in Alzheimer's disease brain. <i>Brain Research</i> , 2012, 1450, 138-147.	1.1	47
227	Resistant to amyloid- β or just waiting for disease to happen?. <i>Alzheimer's Research and Therapy</i> , 2012, 4, 19.	3.0	0
228	Animal Models of Alzheimer Disease. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2012, 2, a006320-a006320.	2.9	336
229	¹⁸ F-Labeled Phenyl diazenyl Benzothiazole for in Vivo Imaging of Neurofibrillary Tangles in Alzheimer's Disease Brains. <i>ACS Medicinal Chemistry Letters</i> , 2012, 3, 58-62.	1.3	33
230	Cognition, glucose metabolism and amyloid burden in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2012, 33, 215-225.	1.5	122
231	Immunotherapy of cerebrovascular amyloidosis in a transgenic mouse model. <i>Neurobiology of Aging</i> , 2012, 33, 432.e1-432.e13.	1.5	24
232	The C-Terminal Repeating Units of CsgB Direct Bacterial Functional Amyloid Nucleation. <i>Journal of Molecular Biology</i> , 2012, 422, 376-389.	2.0	64
233	Alzheimer's disease A β assemblies mediating rapid disruption of synaptic plasticity and memory. <i>Molecular Brain</i> , 2012, 5, 25.	1.3	82
234	Alzheimer's Disease and the Amyloid β -Protein. <i>Progress in Molecular Biology and Translational Science</i> , 2012, 107, 101-124.	0.9	106
235	Amyloid- β Oligomers in Cerebrospinal Fluid are Associated with Cognitive Decline in Patients with Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2012, 29, 171-176.	1.2	95
236	Overlapping profiles of A β peptides in the Alzheimer's disease and pathological aging brains. <i>Alzheimer's Research and Therapy</i> , 2012, 4, 18.	3.0	92
237	The Dying of the Light: Mitochondrial Failure in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2012, 28, 771-781.	1.2	35
238	The Butter Flavorant, Diacetyl, Exacerbates β -Amyloid Cytotoxicity. <i>Chemical Research in Toxicology</i> , 2012, 25, 2083-2091.	1.7	32
239	Protein aggregation and misfolding: good or evil?. <i>Journal of Physics Condensed Matter</i> , 2012, 24, 244101.	0.7	16

#	ARTICLE	IF	CITATIONS
240	Small-molecule BACE1 inhibitors: a patent literature review (2006 – 2011). <i>Expert Opinion on Therapeutic Patents</i> , 2012, 22, 511-540.	2.4	77
241	A β Toxicity in Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2012, 45, 366-378.	1.9	134
242	Early memory deficits precede plaque deposition in APP ^{swe} /PS1 ^{dE9} mice: Involvement of oxidative stress and cholinergic dysfunction. <i>Free Radical Biology and Medicine</i> , 2012, 52, 1443-1452.	1.3	75
243	Huperzine A alleviates synaptic deficits and modulates amyloidogenic and nonamyloidogenic pathways in APP ^{swe} /PS1 ^{dE9} transgenic mice. <i>Journal of Neuroscience Research</i> , 2012, 90, 508-517.	1.3	47
244	Longitudinal assessment of tau and amyloid beta in cerebrospinal fluid of Parkinson disease. <i>Acta Neuropathologica</i> , 2013, 126, 671-682.	3.9	76
245	Apolipoprotein A-I: Insights from redox proteomics for its role in neurodegeneration. <i>Proteomics - Clinical Applications</i> , 2013, 7, 109-122.	0.8	59
246	Green tea catechin leads to global improvement among Alzheimer's disease-related phenotypes in NSE/hAPP-C105 Tg mice. <i>Journal of Nutritional Biochemistry</i> , 2013, 24, 1302-1313.	1.9	60
247	Oligomers, fact or artefact? SDS-PAGE induces dimerization of A β in human brain samples. <i>Acta Neuropathologica</i> , 2013, 125, 549-564.	3.9	74
248	From Soluble A to Progressive A Aggregation: Could Prion-Like Templated Misfolding Play a Role?. <i>Brain Pathology</i> , 2013, 23, 333-341.	2.1	32
249	Polymorph-Specific Kinetics and Thermodynamics of A β -Amyloid Fibril Growth. <i>Journal of the American Chemical Society</i> , 2013, 135, 6860-6871.	6.6	141
250	Neurodegeneration, A β and mood disorders: state of the art and future perspectives. <i>International Journal of Geriatric Psychiatry</i> , 2013, 28, 661-671.	1.3	12
251	Immunotherapy for the treatment of Alzheimer's disease: amyloid- β ; or tau, which is the right target?. <i>ImmunoTargets and Therapy</i> , 2014, 3, 19.	2.7	11
252	Metabolism of amyloid A β peptide and pathogenesis of Alzheimer's disease. <i>Proceedings of the Japan Academy Series B: Physical and Biological Sciences</i> , 2013, 89, 321-339.	1.6	39
253	Amyloid Beta Peptides Differentially Affect Hippocampal Theta Rhythms <i>In Vitro</i> . <i>International Journal of Peptides</i> , 2013, 2013, 1-11.	0.7	19
254	Clinical correlates in an experimental model of repetitive mild brain injury. <i>Annals of Neurology</i> , 2013, 74, 65-75.	2.8	141
255	CB2 Receptor Deficiency Increases Amyloid Pathology and Alters Tau Processing in a Transgenic Mouse Model of Alzheimer's Disease. <i>Molecular Medicine</i> , 2013, 19, 29-36.	1.9	22
256	Accumulation of Intraneuronal A β 42 Peptides Is Associated with Early Changes in Microtubule-Associated Protein 2 in Neurites and Synapses. <i>PLoS ONE</i> , 2013, 8, e51965.	1.1	48
257	Synergistic Interactions between Alzheimer's A β 40 and A β 42 on the Surface of Primary Neurons Revealed by Single Molecule Microscopy. <i>PLoS ONE</i> , 2013, 8, e82139.	1.1	22

#	ARTICLE	IF	CITATIONS
258	Chronochemistry in neurodegeneration. <i>Frontiers in Molecular Neuroscience</i> , 2014, 7, 20.	1.4	7
259	CB2 Receptor Deficiency Increases Amyloid Pathology and Alters Tau Processing in a Transgenic Mouse Model of Alzheimer's Disease. <i>Molecular Medicine</i> , 2014, 20, 29-36.	1.9	55
260	Neurodegenerative disorders: Dysregulation of a carefully maintained balance?. <i>Experimental Gerontology</i> , 2014, 58, 279-291.	1.2	17
261	Amyloid- β efflux from the central nervous system into the plasma. <i>Annals of Neurology</i> , 2014, 76, 837-844.	2.8	199
262	Failure of Perivascular Drainage of β -Amyloid in Cerebral Amyloid Angiopathy. <i>Brain Pathology</i> , 2014, 24, 396-403.	2.1	132
263	Amyloid- β -directed immunotherapy for Alzheimer's disease. <i>Journal of Internal Medicine</i> , 2014, 275, 284-295.	2.7	129
264	Intracerebroventricular Streptozotocin Exacerbates Alzheimer-Like Changes of 3xTg-AD Mice. <i>Molecular Neurobiology</i> , 2014, 49, 547-562.	1.9	85
265	Soluble apoE/ β complex: mechanism and therapeutic target for APOE4-induced AD risk. <i>Molecular Neurodegeneration</i> , 2014, 9, 2.	4.4	98
266	Intraneuronal accumulation of β 42 induces age-dependent slowing of neuronal transmission in <i>Drosophila</i> . <i>Neuroscience Bulletin</i> , 2014, 30, 185-190.	1.5	12
267	Amyloid- β Pathology and APOE Genotype Modulate Retinoid X Receptor Agonist Activity in Vivo. <i>Journal of Biological Chemistry</i> , 2014, 289, 30538-30555.	1.6	82
268	Age-dependent metabolic dysregulation in cancer and Alzheimer's disease. <i>Biogerontology</i> , 2014, 15, 559-577.	2.0	64
269	Insights into the role of the beta-2 microglobulin D-strand in amyloid propensity revealed by mass spectrometry. <i>Molecular BioSystems</i> , 2014, 10, 412-420.	2.9	22
270	Decreasing oxidative stress and neuroinflammation with a multifunctional peptide rescues memory deficits in mice with Alzheimer disease. <i>Free Radical Biology and Medicine</i> , 2014, 74, 50-63.	1.3	50
271	Mixed oligomers and monomeric amyloid- β disrupts endothelial cells integrity and reduces monomeric amyloid- β transport across hCMEC/D3 cell line as an in vitro blood-brain barrier model. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2014, 1842, 1806-1815.	1.8	46
272	Development of a novel cellular model of Alzheimer's disease utilizing neurosphere cultures derived from B6C3-Tg(APP ^{swe} ,PSEN1 ^{dE9})85Dbo/J embryonic mouse brain. <i>SpringerPlus</i> , 2014, 3, 161.	1.2	12
273	Is pathological aging a successful resistance against amyloid-beta or preclinical Alzheimer's disease?. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 24.	3.0	35
274	Soluble amyloid beta levels are elevated in the white matter of Alzheimer's patients, independent of cortical plaque severity. <i>Acta Neuropathologica Communications</i> , 2014, 2, 83.	2.4	39
275	Axonally Synthesized ATF4 Transmits a Neurodegenerative Signal across Brain Regions. <i>Cell</i> , 2014, 158, 1159-1172.	13.5	266

#	ARTICLE	IF	CITATIONS
276	Imaging of amyloid deposition in human brain using positron emission tomography and [18F]FACT: comparison with [11C]PIB. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 745-754.	3.3	19
277	Therapeutic Molecules and Endogenous Ligands Regulate the Interaction between Brain Cellular Prion Protein (PrPC) and Metabotropic Glutamate Receptor 5 (mGluR5). <i>Journal of Biological Chemistry</i> , 2014, 289, 28460-28477.	1.6	70
278	Elucidating the role of DEPTOR in Alzheimer's disease. <i>International Journal of Molecular Medicine</i> , 2014, 34, 1195-1200.	1.8	17
279	Recommendations for Development of New Standardized Forms of Cocoa Breeds and Cocoa Extract Processing for the Prevention of Alzheimer's Disease: Role of Cocoa in Promotion of Cognitive Resilience and Healthy Brain Aging. <i>Journal of Alzheimer's Disease</i> , 2015, 48, 879-889.	1.2	18
280	Re-engineering a neuroprotective, clinical drug as a procognitive agent with high in vivo potency and with GABAA potentiating activity for use in dementia. <i>BMC Neuroscience</i> , 2015, 16, 67.	0.8	12
281	Direct reprogramming of induced neural progenitors: a new promising strategy for AD treatment. <i>Translational Neurodegeneration</i> , 2015, 4, 7.	3.6	10
282	Alzheimer's in 3D culture: Challenges and perspectives. <i>BioEssays</i> , 2015, 37, 1139-1148.	1.2	83
283	Effects of Low Amyloid- β ($A\beta$) Concentration on $A\beta$ 1-42 Oligomers Binding and GluN2B Membrane Expression. <i>Journal of Alzheimer's Disease</i> , 2015, 47, 453-466.	1.2	20
284	Tau Oligomers: The Toxic Player at Synapses in Alzheimer's Disease. <i>Frontiers in Cellular Neuroscience</i> , 2015, 9, 464.	1.8	127
285	Blood-Based Proteomic Biomarkers of Alzheimer's Disease Pathology. <i>Frontiers in Neurology</i> , 2015, 6, 236.	1.1	102
286	Amyloid- β oligomers unveil a novel primate model of sporadic Alzheimer's disease. <i>Frontiers in Neuroscience</i> , 2015, 9, 47.	1.4	2
287	Friends or Foes: Matrix Metalloproteinases and Their Multifaceted Roles in Neurodegenerative Diseases. <i>Mediators of Inflammation</i> , 2015, 2015, 1-27.	1.4	154
288	Vitamin D and Alzheimer's Disease: Neurocognition to Therapeutics. <i>International Journal of Alzheimer's Disease</i> , 2015, 2015, 1-11.	1.1	63
289	A molecular chaperone breaks the catalytic cycle that generates toxic $A\beta$ oligomers. <i>Nature Structural and Molecular Biology</i> , 2015, 22, 207-213.	3.6	373
290	APOE ϵ 4 modulated $A\beta$ -induced neuroinflammation in Alzheimer's disease: current landscape, novel data, and future perspective. <i>Journal of Neurochemistry</i> , 2015, 133, 465-488.	2.1	123
291	Localization and Trafficking of Amyloid- β Protein Precursor and Secretases: Impact on Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 45, 329-347.	1.2	64
292	Cu ²⁺ accentuates distinct misfolding of $A\beta$ (1-40) and $A\beta$ (1-42) peptides, and potentiates membrane disruption. <i>Biochemical Journal</i> , 2015, 466, 233-242.	1.7	56
293	Icariin decreases both APP and $A\beta$ levels and increases neurogenesis in the brain of Tg2576 mice. <i>Neuroscience</i> , 2015, 304, 29-35.	1.1	46

#	ARTICLE	IF	CITATIONS
294	Dementia of the eye: the role of amyloid beta in retinal degeneration. <i>Eye</i> , 2015, 29, 1013-1026.	1.1	133
295	Amyloid-beta neuroprotection mediated by a targeted antioxidant. <i>Scientific Reports</i> , 2015, 4, 4983.	1.6	32
296	Alzheimer's disease clinical trials: past failures and future opportunities. <i>Clinical Investigation</i> , 2015, 5, 297-309.	0.0	15
297	The aqueous phase of Alzheimer's disease brain contains assemblies built from \hat{A}^{144} and \hat{A}^{147} kDa \hat{A}^{12} species. <i>Alzheimer's and Dementia</i> , 2015, 11, 1286-1305.	0.4	54
298	Signal loss due to oligomerization in ELISA analysis of amyloid-beta can be recovered by a novel sample pre-treatment method. <i>MethodsX</i> , 2015, 2, 112-123.	0.7	19
299	APOE4 enhances age-dependent decline in cognitive function by down-regulating an NMDA receptor pathway in EFAD-Tg mice. <i>Molecular Neurodegeneration</i> , 2015, 10, 7.	4.4	79
300	The role and therapeutic targeting of \hat{A}^{1-42} , \hat{A}^{1-40} and \hat{A}^{1-38} -secretase in Alzheimer's disease. <i>Future Science OA</i> , 2015, 1, FSO11.	0.9	75
301	Role of amyloid- \hat{A}^{12} CSF levels in cognitive deficit in MS. <i>Clinica Chimica Acta</i> , 2015, 449, 23-30.	0.5	27
302	Alzheimer's Disease and Mechanism-Based Attempts to Enhance Cognition. , 2015, , 193-231.		0
303	Protein structures in Alzheimer's disease: The basis for rationale therapeutic design. <i>Archives of Biochemistry and Biophysics</i> , 2015, 588, 1-14.	1.4	20
304	Accumulation of amyloid- \hat{A}^{12} in the cerebellar cortex of essential tremor patients. <i>Neurobiology of Disease</i> , 2015, 82, 397-408.	2.1	16
305	Extra-virgin olive oil attenuates amyloid- \hat{A}^{12} and tau pathologies in the brains of TgSwDI mice. <i>Journal of Nutritional Biochemistry</i> , 2015, 26, 1479-1490.	1.9	80
306	Cortical pyroglutamate amyloid- \hat{A}^{12} levels and cognitive decline in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2015, 36, 12-19.	1.5	29
307	Decreased Myelinated Fibers in the Hippocampal Dentate Gyrus of the Tg2576 Mouse Model of Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2016, 13, 1040-1047.	0.7	9
308	Soluble Amyloid- \hat{A}^{142} Stimulates Glutamate Release through Activation of the \hat{A}^{7} Nicotinic Acetylcholine Receptor. <i>Journal of Alzheimer's Disease</i> , 2016, 53, 337-347.	1.2	40
309	Curcumin against amyloid pathology in mental health and brain composition. , 2016, , 487-505.		0
310	Human whole genome genotype and transcriptome data for Alzheimer's and other neurodegenerative diseases. <i>Scientific Data</i> , 2016, 3, 160089.	2.4	361
311	<i>A\hat{A}^{12}</i> -Immunotherapeutic strategies: a wide range of approaches for Alzheimer's disease treatment. <i>Expert Reviews in Molecular Medicine</i> , 2016, 18, e13.	1.6	34

#	ARTICLE	IF	CITATIONS
312	3D culture models of Alzheimer's disease: a road map to a 'secure-in-a-dish'. <i>Molecular Neurodegeneration</i> , 2016, 11, 75.	4.4	109
313	Improved Neuroprotection Provided by Drug Combination in Neurons Exposed to Cell-Derived Soluble Amyloid- β Peptide. <i>Journal of Alzheimer's Disease</i> , 2016, 52, 975-987.	1.2	8
314	Immunization with Small Amyloid- β -derived Cyclopeptide Conjugates Diminishes Amyloid- β -Induced Neurodegeneration in Mice. <i>Journal of Alzheimer's Disease</i> , 2016, 52, 1111-1123.	1.2	5
315	Late age increase in soluble amyloid-beta levels in the APP23 mouse model despite steady-state levels of amyloid-beta-producing proteins. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2016, 1862, 105-112.	1.8	11
316	What amyloid ligands can tell us about molecular polymorphism and disease. <i>Neurobiology of Aging</i> , 2016, 42, 205-212.	1.5	11
317	Mathematical model on Alzheimer's disease. <i>BMC Systems Biology</i> , 2016, 10, 108.	3.0	86
318	Mapping synaptic glutamate transporter dysfunction in vivo to regions surrounding A β plaques by iGluSnFR two-photon imaging. <i>Nature Communications</i> , 2016, 7, 13441.	5.8	105
319	Targeting A β Receptors to Modify Alzheimer's Disease Progression. , 2016, , 227-250.		0
320	Oligomers of Amyloid β Prevent Physiological Activation of the Cellular Prion Protein-Metabotropic Glutamate Receptor 5 Complex by Glutamate in Alzheimer Disease. <i>Journal of Biological Chemistry</i> , 2016, 291, 17112-17121.	1.6	65
321	β -Amyloid induces nuclear protease-mediated lamin fragmentation independent of caspase activation. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2016, 1863, 1189-1199.	1.9	10
322	β -Amyloid pathogenesis: Chemical properties versus cellular levels. <i>Alzheimer's and Dementia</i> , 2016, 12, 184-194.	0.4	28
323	Glimepiride protects neurons against amyloid- β -induced synapse damage. <i>Neuropharmacology</i> , 2016, 101, 225-236.	2.0	37
324	Antibody Therapeutics Targeting A β and Tau. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2017, 7, a024331.	2.9	39
325	Do anti-amyloid beta protein antibody cross reactivities confound Alzheimer disease research?. <i>Journal of Negative Results in BioMedicine</i> , 2017, 16, 1.	1.4	51
326	Flexible N-Termini of Amyloid β -Protein Oligomers: A Link between Structure and Activity?. <i>Israel Journal of Chemistry</i> , 2017, 57, 651-664.	1.0	8
327	Pharmacogenomics of angiotensin receptor/neprilysin inhibitor and its long-term side effects. <i>Cardiovascular Therapeutics</i> , 2017, 35, e12272.	1.1	20
328	A Translational Systems Pharmacology Model for A β Kinetics in Mouse, Monkey, and Human. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2017, 6, 666-675.	1.3	11
329	Neurofibrillary Tangles of A β _{x40} in Alzheimer's Disease Brains. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 661-667.	1.2	22

#	ARTICLE	IF	CITATIONS
330	Biochemically-defined pools of amyloid- β^2 in sporadic Alzheimer's disease: correlation with amyloid PET. <i>Brain</i> , 2017, 140, 1486-1498.	3.7	123
331	Long-term neprilysin inhibition " implications for ARNIs. <i>Nature Reviews Cardiology</i> , 2017, 14, 171-186.	6.1	111
332	Overexpression of Kinesin Superfamily Motor Proteins in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 1511-1524.	1.2	29
333	Perturbation of the F19-L34 Contact in Amyloid β^2 (1-40) Fibrils Induces Only Local Structural Changes but Abolishes Cytotoxicity. <i>Journal of Physical Chemistry Letters</i> , 2017, 8, 4740-4745.	2.1	14
334	Tuning the stereo-hindrance of a curcumin scaffold for the selective imaging of the soluble forms of amyloid beta species. <i>Chemical Science</i> , 2017, 8, 7710-7717.	3.7	69
335	SEN1500, a novel oral amyloid- β^2 aggregation inhibitor, attenuates brain pathology in a mouse model of Alzheimer's disease. <i>Neuroscience Letters</i> , 2017, 660, 96-102.	1.0	3
336	Studying the Progression of Amyloid Pathology and Its Therapy Using Translational Longitudinal Model of Accumulation and Distribution of Amyloid Beta. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2017, 6, 676-685.	1.3	11
337	CART modulates beta-amyloid metabolism-associated enzymes and attenuates memory deficits in APP/PS1 mice. <i>Neurological Research</i> , 2017, 39, 885-894.	0.6	22
338	A modified formulation of Huanglian-Jie-Du-Tang reduces memory impairments and β^2 -amyloid plaques in a triple transgenic mouse model of Alzheimer's disease. <i>Scientific Reports</i> , 2017, 7, 6238.	1.6	35
339	Towards the improvement in stability of an anti- β^2 single-chain variable fragment, scFv-h3D6, as a way to enhance its therapeutic potential. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 167-175.	1.4	8
340	Neurovascular Alterations in Alzheimer's Disease: Transporter Expression Profiles and CNS Drug Access. <i>AAPS Journal</i> , 2017, 19, 940-956.	2.2	16
341	Local cholinergic-GABAergic circuitry within the basal forebrain is modulated by galanin. <i>Brain Structure and Function</i> , 2017, 222, 1385-1400.	1.2	5
342	Overexpression of serum amyloid a 1 induces depressive-like behavior in mice. <i>Brain Research</i> , 2017, 1654, 55-65.	1.1	22
343	Distinct spatiotemporal accumulation of N-truncated and full-length amyloid- β^2 42 in Alzheimer's disease. <i>Brain</i> , 2017, 140, 3301-3316.	3.7	14
344	Perspective, Summary, and Directions for Future Research on Alzheimer's Disease. , 2017, , 361-386.		0
345	Numerical Simulations Reveal Randomness of Cu(II) Induced β^2 Peptide Dimerization under Conditions Present in Glutamatergic Synapses. <i>PLoS ONE</i> , 2017, 12, e0170749.	1.1	19
346	Production of an anti- β^2 antibody fragment in <i>Pichia pastoris</i> and in vitro and in vivo validation of its therapeutic effect. <i>PLoS ONE</i> , 2017, 12, e0181480.	1.1	25
347	Oligomeric amyloid-beta induces MAPK-mediated activation of brain cytosolic and calcium-independent phospholipase A2 in a spatial-specific manner. <i>Acta Neuropathologica Communications</i> , 2017, 5, 56.	2.4	38

#	ARTICLE	IF	CITATIONS
348	Diffusible, highly bioactive oligomers represent a critical minority of soluble A β in Alzheimer's disease brain. <i>Acta Neuropathologica</i> , 2018, 136, 19-40.	3.9	100
349	A β -oligomer uptake and the resulting inflammatory response in adult human astrocytes are precluded by an anti-A β single chain variable fragment in combination with an apoE mimetic peptide. <i>Molecular and Cellular Neurosciences</i> , 2018, 89, 49-59.	1.0	21
350	Increased Vulnerability of the Hippocampus in Transgenic Mice Overexpressing APP and Triple Repeat Tau. <i>Journal of Alzheimer's Disease</i> , 2018, 61, 1201-1219.	1.2	4
351	Novel targets in Alzheimer's disease: A special focus on microglia. <i>Pharmacological Research</i> , 2018, 130, 402-413.	3.1	46
352	Depletion of amyloid β peptides from solution by sequestration within fibril-seeded hydrogels. <i>Protein Science</i> , 2018, 27, 1218-1230.	3.1	6
353	Prion-like seeding and nucleation of intracellular amyloid- β . <i>Neurobiology of Disease</i> , 2018, 113, 1-10.	2.1	60
354	Immunotherapy for neurodegenerative diseases: the Alzheimer's disease paradigm. <i>Current Opinion in Chemical Engineering</i> , 2018, 19, 59-67.	3.8	8
355	Interactions of amyloid- β peptides on lipid bilayer studied by single molecule imaging and tracking. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2018, 1860, 1616-1624.	1.4	26
356	The Effects of N-terminal Mutations on β -amyloid Peptide Aggregation and Toxicity. <i>Neuroscience</i> , 2018, 379, 177-188.	1.1	20
357	Rosuvastatin ameliorates cognitive impairment in rats fed with high-salt and cholesterol diet via inhibiting acetylcholinesterase activity and amyloid beta peptide aggregation. <i>Human and Experimental Toxicology</i> , 2018, 37, 399-411.	1.1	28
358	Hippocampal Proteomic Analysis Reveals Distinct Pathway Deregulation Profiles at Early and Late Stages in a Rat Model of Alzheimer's-Like Amyloid Pathology. <i>Molecular Neurobiology</i> , 2018, 55, 3451-3476.	1.9	21
359	Increased Insoluble Amyloid- β Induces Negligible Cognitive Deficits in Old AppNL/NL Knock-In Mice. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 801-809.	1.2	8
360	Past and Future of Drug Treatments for Alzheimer's Disease. <i>Journal of Korean Neuropsychiatric Association</i> , 2018, 57, 30.	0.2	6
361	NMDA receptors mediate synaptic depression, but not spine loss in the dentate gyrus of adult amyloid Beta (A β) overexpressing mice. <i>Acta Neuropathologica Communications</i> , 2018, 6, 110.	2.4	26
362	Immunotherapy to improve cognition and reduce pathological species in an Alzheimer's disease mouse model. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 54.	3.0	24
363	Metabolic Abnormalities of Erythrocytes as a Risk Factor for Alzheimer's Disease. <i>Frontiers in Neuroscience</i> , 2017, 11, 728.	1.4	23
364	Safety, tolerability and immunogenicity of an active anti-A β 40 vaccine (ABvac40) in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase I trial. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 12.	3.0	72
365	Distinctive temporal profiles of detergent-soluble and -insoluble tau and A β species in human Alzheimer's disease. <i>Brain Research</i> , 2018, 1699, 121-134.	1.1	19

#	ARTICLE	IF	CITATIONS
366	Doxycycline counteracts neuroinflammation restoring memory in Alzheimer's disease mouse models. <i>Neurobiology of Aging</i> , 2018, 70, 128-139.	1.5	52
367	Impact of TREM2 risk variants on brain region-specific immune activation and plaque microenvironment in Alzheimer's disease patient brain samples. <i>Acta Neuropathologica</i> , 2019, 138, 613-630.	3.9	68
368	In Vivo Assessment of Retinal Biomarkers by Hyperspectral Imaging: Early Detection of Alzheimer's Disease. <i>ACS Chemical Neuroscience</i> , 2019, 10, 4492-4501.	1.7	37
369	History and progress of hypotheses and clinical trials for Alzheimer's disease. <i>Signal Transduction and Targeted Therapy</i> , 2019, 4, 29.	7.1	370
370	Dietary supplementation of a high-temperature-processed green tea extract attenuates cognitive impairment in PS2 and Tg2576 mice. <i>Bioscience, Biotechnology and Biochemistry</i> , 2019, 83, 2364-2371.	0.6	11
371	Differential activation of the mTOR/autophagy pathway predicts cognitive performance in APP/PS1 mice. <i>Neurobiology of Aging</i> , 2019, 83, 105-113.	1.5	25
372	Brains of rhesus monkeys display A β deposits and glial pathology while lacking A β dimers and other Alzheimer's pathologies. <i>Aging Cell</i> , 2019, 18, e12978.	3.0	17
373	X-ray Absorption Spectroscopy Investigations of Copper(II) Coordination in the Human Amyloid β Peptide. <i>Inorganic Chemistry</i> , 2019, 58, 6294-6311.	1.9	30
374	Fluorescence Chemicals To Detect Insoluble and Soluble Amyloid- β Aggregates. <i>ACS Chemical Neuroscience</i> , 2019, 10, 2647-2657.	1.7	39
375	β -Sheet secondary structure in amyloid β -peptide drives aggregation and toxicity in Alzheimer's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 8895-8900.	3.3	118
376	Association of Cortical β -Amyloid Protein in the Absence of Insoluble Deposits With Alzheimer Disease. <i>JAMA Neurology</i> , 2019, 76, 818.	4.5	25
377	Glutiramer acetate reduces infarct volume in diabetic mice with cerebral ischemia and prevents long-term memory loss. <i>Brain, Behavior, and Immunity</i> , 2019, 80, 315-327.	2.0	18
378	In vivo localization of human acetylcholinesterase-derived species in a β -sheet conformation at the core of senile plaques in Alzheimer's disease. <i>Journal of Biological Chemistry</i> , 2019, 294, 6253-6272.	1.6	19
379	Pyroglutamation of amyloid- β ₁₋₄₂ (A β ₁₋₄₂) followed by A β ₁₋₄₀ deposition underlies plaque polymorphism in progressing Alzheimer's disease pathology. <i>Journal of Biological Chemistry</i> , 2019, 294, 6719-6732.	1.6	49
380	Different aspects of Alzheimer's disease-related amyloid β -peptide pathology and their relationship to amyloid positron emission tomography imaging and dementia. <i>Acta Neuropathologica Communications</i> , 2019, 7, 178.	2.4	29
381	Voluntary Wheel Running Reduces Amyloid- β ₄₂ and Rescues Behavior in Aged Tg2576 Mouse Model of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 359-374.	1.2	6
382	A Pilot Study Comparing Effects of Bifrontal Versus Bitemporal Transcranial Direct Current Stimulation in Mild Cognitive Impairment and Mild Alzheimer Disease. <i>Journal of ECT</i> , 2020, 36, 211-215.	0.3	15
383	Passive immunotherapies targeting A β and tau in Alzheimer's disease. <i>Neurobiology of Disease</i> , 2020, 144, 105010.	2.1	81

#	ARTICLE	IF	CITATIONS
385	Inhibition of Aquaporin 4 Decreases Amyloid A β 240 Drainage Around Cerebral Vessels. <i>Molecular Neurobiology</i> , 2020, 57, 4720-4734.	1.9	32
386	A microfiber scaffold-based 3D <i>in vitro</i> human neuronal culture model of Alzheimer's disease. <i>Biomaterials Science</i> , 2020, 8, 4861-4874.	2.6	16
387	Therapeutic Targeting Strategies for Early- to Late-Staged Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9591.	1.8	24
388	Amyloid- β 242/40 ratio drives tau pathology in 3D human neural cell culture models of Alzheimer's disease. <i>Nature Communications</i> , 2020, 11, 1377.	5.8	88
389	The Hypothesis That Refuses to Die. , 2020, , 95-104.		0
391	The Shaky Six and the "Second Reality", 2020, , 1-10.		0
392	Pieces of a Puzzle?. , 2020, , 11-24.		0
393	Disease "Redefinition": A Tough Pill to Swallow. , 2020, , 25-32.		0
394	Disease Subtypes: The Promise and the Fallacy. , 2020, , 33-40.		2
395	Protein Paradox. , 2020, , 41-56.		0
396	The Fault in Our Models. , 2020, , 57-70.		0
397	Biomarkers: The Promise and the Fallacy. , 2020, , 71-80.		0
398	Lessons from Oncology. , 2020, , 81-86.		0
399	Symptomatic vs. Disease-Modifying Therapies. , 2020, , 87-94.		3
400	Our Living Dissonance. , 2020, , 105-110.		0
401	The Scientific and Lay Narratives. , 2020, , 111-124.		0
402	Challenges Viewed from Afar. , 2020, , 125-132.		0
403	The Moonshot: Population-Based Studies of Aging. , 2020, , 133-138.		0

#	ARTICLE	IF	CITATIONS
404	Predictions for the 2020s and Beyond. , 2020, , 139-147.		0
405	Note Added at Press Time “ Reviving LOF. , 2020, , 150-150.		0
408	ApoE mimetic improves pathology and memory in a model of Alzheimer’s disease. Brain Research, 2020, 1733, 146685.	1.1	22
409	Development of the clinical candidate PBD-C06, a humanized pGlu3-A β -specific antibody against Alzheimer’s disease with reduced complement activation. Scientific Reports, 2020, 10, 3294.	1.6	17
410	Nrf2 Suppresses Oxidative Stress and Inflammation in <i>App</i> Knock-In Alzheimer’s Disease Model Mice. Molecular and Cellular Biology, 2020, 40, .	1.1	98
411	The Erythrocytic Hypothesis of Brain Energy Crisis in Sporadic Alzheimer Disease: Possible Consequences and Supporting Evidence. Journal of Clinical Medicine, 2020, 9, 206.	1.0	8
412	Overexpression of protein kinase M $\bar{1}\eta$ in the hippocampus mitigates Alzheimer’s disease-related cognitive deficit in rats. Brain Research Bulletin, 2021, 166, 64-72.	1.4	5
413	Characterization of Homogeneous and Heterogeneous Amyloid- β 42 Oligomer Preparations with Biochemical Methods and Infrared Spectroscopy Reveals a Correlation between Infrared Spectrum and Oligomer Size. ACS Chemical Neuroscience, 2021, 12, 473-488.	1.7	27
414	Mitochondrial abnormalities in neurological disorders. , 2021, , 193-245.		0
415	Neuroinflammation in Alzheimer's disease and beneficial action of luteolin. BioFactors, 2021, 47, 207-217.	2.6	21
416	Mural Cells: Potential Therapeutic Targets to Bridge Cardiovascular Disease and Neurodegeneration. Cells, 2021, 10, 593.	1.8	8
417	Generation of a humanized A β expressing mouse demonstrating aspects of Alzheimer’s disease-like pathology. Nature Communications, 2021, 12, 2421.	5.8	53
419	Neuroprotective Effects of Asparagus officinalis Stem Extract in Transgenic Mice Overexpressing Amyloid Precursor Protein. Journal of Immunology Research, 2021, 2021, 1-10.	0.9	5
420	Alzheimer’s Disease Animal Models: Elucidation of Biomarkers and Therapeutic Approaches for Cognitive Impairment. International Journal of Molecular Sciences, 2021, 22, 5549.	1.8	20
421	Hippocampal Somatostatin Interneurons, Long-Term Synaptic Plasticity and Memory. Frontiers in Neural Circuits, 2021, 15, 687558.	1.4	32
422	Refining the amyloid β peptide and oligomer fingerprint ambiguities in Alzheimer’s disease: Mass spectrometric molecular characterization in brain, cerebrospinal fluid, blood, and plasma. Journal of Neurochemistry, 2021, 159, 234-257.	2.1	8
423	Development of grape polyphenols as multi-targeting strategies for Alzheimer's disease. Neurochemistry International, 2021, 147, 105046.	1.9	16
424	IntelliCage Automated Behavioral Phenotyping Reveals Behavior Deficits in the 3xTg-AD Mouse Model of Alzheimer’s Disease Associated With Brain Weight. Frontiers in Aging Neuroscience, 2021, 13, 720214.	1.7	12

#	ARTICLE	IF	CITATIONS
425	Quantitative Approaches to Amyloid Imaging. <i>Methods in Molecular Biology</i> , 2011, 680, 201-225.	0.4	4
426	Rapid Generation of Dityrosine Cross-linked A β Oligomers via Cu-Redox Cycling. <i>Methods in Molecular Biology</i> , 2012, 849, 3-10.	0.4	6
427	The Role of A β and Tau Oligomers in the Pathogenesis of Alzheimer's Disease. , 2012, , 135-188.		5
428	Neuronal Protein Trafficking in Alzheimer's Disease and Niemann-Pick Type C Disease. , 2007, , 391-411.		2
430	Scara1 deficiency impairs clearance of soluble amyloid- β by mononuclear phagocytes and accelerates Alzheimer's-like disease progression. <i>Nature Communications</i> , 2013, 4, 2030.	5.8	162
432	Anti-A β 42- and anti-A β 40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model. <i>Journal of Clinical Investigation</i> , 2005, 116, 193-201.	3.9	172
433	Cholinergic dysfunction in a mouse model of Alzheimer disease is reversed by an anti-A β antibody. <i>Journal of Clinical Investigation</i> , 2006, 116, 825-832.	3.9	111
434	Soluble amyloid beta levels are elevated in the white matter of Alzheimer's patients, independent of cortical plaque severity. <i>Acta Neuropathologica Communications</i> , 2014, 2, 83.	2.4	33
436	Zinc Overload Enhances APP Cleavage and A β Deposition in the Alzheimer Mouse Brain. <i>PLoS ONE</i> , 2010, 5, e15349.	1.1	79
437	A Reliable Way to Detect Endogenous Murine β -Amyloid. <i>PLoS ONE</i> , 2013, 8, e55647.	1.1	32
438	Effects of NR1H3 Genetic Variation on the Expression of Liver X Receptor α and the Progression of Alzheimer's Disease. <i>PLoS ONE</i> , 2013, 8, e80700.	1.1	16
439	Functional Amyloids and their Possible Influence on Alzheimer Disease. <i>Discoveries</i> , 2017, 5, e79.	1.5	9
440	Recapitulating Amyloid β and Tau Pathology in Human Neural Cell Culture Models—Clinical Implications. <i>US Neurology</i> , 2015, 11, 102.	0.2	19
441	Early and progressive deficit of neuronal activity patterns in a model of local amyloid pathology in mouse prefrontal cortex. <i>Aging</i> , 2016, 8, 3430-3449.	1.4	10
442	Phytoconstituents and their Possible Mechanistic Profile for Alzheimer's Disease – A Literature Review. <i>Current Drug Targets</i> , 2019, 20, 263-291.	1.0	3
443	Protein Misfolding and Aggregation in Alzheimer's Disease and Type 2 Diabetes Mellitus. <i>CNS and Neurological Disorders - Drug Targets</i> , 2014, 13, 1280-1293.	0.8	138
444	Amyloid Beta Annular Protofibrils in Cell Processes and Synapses Accumulate with Aging and Alzheimer-Associated Genetic Modification. <i>International Journal of Alzheimer's Disease</i> , 2009, 2009, 1-7.	1.1	18
445	Synaptic dysfunction in Alzheimer's disease: the effects of amyloid beta on synaptic vesicle dynamics as a novel target for therapeutic intervention. <i>Neural Regeneration Research</i> , 2018, 13, 616.	1.6	106

#	ARTICLE	IF	CITATIONS
447	Methionine Sulfoxide Reductase System. <i>Oxidative Stress and Disease</i> , 2005, , 199-212.	0.3	0
449	The Impact of HAART on Advanced Brain Aging: Implications for Mitochondrial Dysfunction and APP Processing. <i>Journal of Antivirals & Antiretrovirals</i> , 2013, 05, .	0.1	1
450	Protein Misfolding and Amyloid Formation in Alzheimer's Disease. , 2015, , 119-135.		0
453	Plaque-Associated Oligomeric Amyloid-Beta Drives Early Synaptotoxicity in APP/PS1 Mice Hippocampus: Ultrastructural Pathology Analysis. <i>Frontiers in Neuroscience</i> , 2021, 15, 752594.	1.4	15
454	Mouse Model for Alzheimer's Disease. , 2008, , 191-199.		0
455	Physiologic and Neurotoxic Properties of A β 2 Peptides. , 2007, , 179-197.		0
458	Amyloid-beta Alzheimer targets - protein processing, lipid rafts, and amyloid-beta pores. <i>Yale Journal of Biology and Medicine</i> , 2016, 89, 5-21.	0.2	71
460	Importance of CSF-based A β 2 clearance with age in humans increases with declining efficacy of blood-brain barrier/proteolytic pathways. <i>Communications Biology</i> , 2022, 5, 98.	2.0	22
461	New Perspectives for Treatment in Alzheimer's Disease. , 2022, , 199-225.		0
462	Chronic PPAR γ 3 Stimulation Shifts Amyloidosis to Higher Fibrillarity but Improves Cognition. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 854031.	1.7	5
463	Amyloid-Related Imaging Abnormalities With Anti-amyloid Antibodies for the Treatment of Dementia Due to Alzheimer's Disease. <i>Frontiers in Neurology</i> , 2022, 13, 862369.	1.1	43
464	Elevated amyloid beta disrupts the nanoscale organization and function of synaptic vesicle pools in hippocampal neurons. <i>Cerebral Cortex</i> , 2023, 33, 1263-1276.	1.6	5
465	MUTYH Actively Contributes to Microglial Activation and Impaired Neurogenesis in the Pathogenesis of Alzheimer's Disease. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-30.	1.9	17
466	Amyloid- β 2 Oligomers: Multiple Moving Targets. <i>Biophysica</i> , 2022, 2, 91-110.	0.6	17
467	Artesunate restores mitochondrial fusion-fission dynamics and alleviates neuronal injury in Alzheimer's disease models. <i>Journal of Neurochemistry</i> , 2022, 162, 290-304.	2.1	12
468	Molecular determinants for amyloid fibril formation: lessons from lung surfactant protein C. <i>Swiss Medical Weekly</i> , 0, , .	0.8	5
469	Molecular Tweezers: Supramolecular Hosts with Broad-Spectrum Biological Applications. <i>Pharmacological Reviews</i> , 2023, 75, 263-308.	7.1	4
470	A β 242 oligomer-specific antibody ALZ-201 reduces the neurotoxicity of Alzheimer's disease brain extracts. <i>Alzheimer's Research and Therapy</i> , 2022, 14, .	3.0	3

#	ARTICLE	IF	CITATIONS
471	A Function of Amyloid- β^2 in Mediating Activity-Dependent Axon/Synapse Competition May Unify Its Roles in Brain Physiology and Pathology. <i>Journal of Alzheimer's Disease</i> , 2023, , 1-29.	1.2	2
472	Genetic removal of synaptic Zn ²⁺ impairs cognition, alters neurotrophic signaling and induces neuronal hyperactivity. <i>Frontiers in Neurology</i> , 0, 13, .	1.1	0
473	Apicidin attenuates memory deficits by reducing the A β^2 load in <sc>APP</sc>/<sc>PS1</sc> mice. <i>CNS Neuroscience and Therapeutics</i> , 2023, 29, 1300-1311.	1.9	2
475	Extracellular Vesicle Treatment Alleviates Neurodevelopmental and Neurodegenerative Pathology in Cortical Spheroid Model of Down Syndrome. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3477.	1.8	1
476	Protein Self-Assembly at the Liquid-Surface Interface. Surface-Mediated Aggregation Catalysis. <i>Journal of Physical Chemistry B</i> , 2023, 127, 1880-1889.	1.2	0
477	Dityrosine cross-linking and its potential roles in Alzheimer's disease. <i>Frontiers in Neuroscience</i> , 0, 17, .	1.4	2
478	Effects of Current Psychotropic Drugs on Inflammation and Immune System. <i>Advances in Experimental Medicine and Biology</i> , 2023, , 407-434.	0.8	0
479	Molecular Imaging in Neurology. , 2023, , 375-423.		0
480	Rapid, scalable assay of amylin- β^2 amyloid co-aggregation in brain tissue and blood. <i>Journal of Biological Chemistry</i> , 2023, 299, 104682.	1.6	3